Akero Therapeutics Valuation
| AKRO Stock | USD 32.10 0.07 0.22% |
At this time, the firm appears to be undervalued. Akero Therapeutics shows a prevailing Real Value of $37.25 per share. The current price of the firm is $32.1. Our model approximates the value of Akero Therapeutics from analyzing the firm fundamentals such as return on equity of -0.36, and Current Valuation of 1.56 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Akero Therapeutics' valuation include:
Price Book 3.0346 | Enterprise Value 1.6 B | Enterprise Value Ebitda (6.77) |
Undervalued
Today
Please note that Akero Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Akero Therapeutics is based on 3 months time horizon. Increasing Akero Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Akero Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Akero Stock. However, Akero Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 32.1 | Real 37.25 | Target 43.56 | Hype 31.99 | Naive 32.4 |
The intrinsic value of Akero Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Akero Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Akero Therapeutics helps investors to forecast how Akero stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Akero Therapeutics more accurately as focusing exclusively on Akero Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Akero Therapeutics' intrinsic value based on its ongoing forecasts of Akero Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Akero Therapeutics' closest peers.
Akero Therapeutics Cash |
|
Akero Valuation Trend
Knowing Akero Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Akero Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Akero Therapeutics Total Value Analysis
Akero Therapeutics is presently projected to have valuation of 1.56 B with market capitalization of 2.25 B, debt of 26.3 M, and cash on hands of 180.72 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Akero Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.56 B | 2.25 B | 26.3 M | 180.72 M |
Akero Therapeutics Asset Utilization
One of the ways to look at asset utilization of Akero is to check how much profit was generated for every dollar of assets it reports. Akero Therapeutics shows a negative utilization of assets of -0.23 percent, losing $0.002317 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Akero Therapeutics shows how unproductive it operates for each dollar spent on its assets.Akero Therapeutics Ownership Allocation
The majority of Akero Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Akero Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Akero Therapeutics. Please pay attention to any change in the institutional holdings of Akero Therapeutics as this could imply that something significant has changed or is about to change at the company.Akero Therapeutics Profitability Analysis
Net Loss for the year was (151.76 M) with profit before overhead, payroll, taxes, and interest of 0.About Akero Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Akero Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Akero Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Akero Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Akero Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Akero Therapeutics. We calculate exposure to Akero Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Akero Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -29 K | -30.4 K |
Akero Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 52.6 M |
Akero Therapeutics Current Valuation Indicators
Akero Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Akero Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Akero Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Akero Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Akero Therapeutics' worth.When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.